Sign in
Taking peopleNo phase

Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease

Key facts

Who runs it
University Hospital, Lille
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
450 people, planned
Started
25 Dec 2014
Expected to end
Sept 2027
Type of study
Interventional, 3 groups
Treatments tested
  • collection of liver biopsies collection of blood samples
Record updated
22 May 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • group A: patients with acute alcoholic hepatitis
  • Active alcohol abuse defined by DSM IV and excessive alcohol consumption prior to admission (> 60 g per day for men and> 40 g per day for women)
  • Moderate elevation of transaminases (less than 500 U / L) with a typical ASAT / ALAT ratio of 2: 1
  • Bilirubin> 50 mg / l
  • Absence of autoimmune liver disease (ANA <1/80, AML <1/80, LKM1 neg, AAM neg)
  • Absence of hepatitis B and C and HIV infection (negative anti-HIV antibodies, negative HBsAg, negative HCV PCR)
  • Patients with other acute complications than alcoholic hepatitis may be included (eg, digestive hemorrhage, acute renal failure, infection, etc.)
  • Because there is no validated noninvasive tool for the diagnosis of alcoholic hepatitis, histological confirmation is required in all patients (preferably by transjugular biopsy): alcoholic hepatitis will be diagnosed on the presence of the following histological characteristics: Hepatocellular lesions (ballooning, Mallory body)/ Inflammatory infiltrate with polymorphonuclear neutrophils
  • group B1: patients with alcoholic cirrhosis
  • Decompensated or non-decompensated alcoholic cirrhosis, defined according to the HAS guidelines, ie by a liver biopsy or a cluster of clinico-biological arguments (www.has-sante.fr)
  • group B2: patients free from chronic liver disease
  • Justification of blood and liver sampling for the management of a pathology other than chronic liver disease (eg liver metastasis of digestive cancer occurring on healthy liver)

Who cannot take part

  • Patients with hepatocellular carcinoma of progressive non-hepatic cancer
  • Presence of anti-HCV antibodies by positive PCR
  • Presence of antibodies to HIV 1 +2
  • Alcoholic liver disease
  • Presence of anti-HCV antibodies by positive PCR
  • Presence of antibodies to HIV 1 +2
  • For groups A and B1:
  • Presence of HBsAg
  • Pregnancy
  • for group B2:
  • Presence of HBsAg
  • Pregnancy

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main objective of this study is the comparison of the profile of the pro-inflammatory cytokines at the patients suffering from an alcoholic hepatitis to that of two groups witnesses: patients suffering from an alcoholic cirrhosis and unhurt patients of chronic liver disease

The 3 groups in the trial

  • acute alcoholic hepatitisOther group

    collection of liver biopsies collection of blood samples in patients with acute alcoholic hepatitis (group A)

    Treatment: collection of liver biopsies collection of blood samples

  • Alcoholic cirrhosisOther group

    collection of liver biopsies collection of blood samples in patients with alcoholic cirrhosis (group B1)

    Treatment: collection of liver biopsies collection of blood samples

  • Without chronic liver diseaseOther group

    collection of liver biopsies collection of blood samples in patients without chronic liver disease (group B2)

    Treatment: collection of liver biopsies collection of blood samples

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT03773887, who can take part
Record updated
22 May 2026